EU Okays CV Benefit Labeling for Canagliflozin in Diabetes

The European Commission has granted approval for the addition of positive cardiovascular outcomes data on the label of the SGLT2 inhibitor canagliflozin (Invokana, Vokanamet, Janssen). Inclusion of the data, from the company’s CANVAS clinical trial p https://www.medscape.com/viewarticle/902311